Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
about
Juvenile Idiopathic Arthritis in the Era of International Cooperation.Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation CollA safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?Macrophage activation syndrome in the era of biologic therapy.Pediatric acute liver failure of undetermined cause: A research workshop.Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.New frontiers in the treatment of systemic juvenile idiopathic arthritis.Combination Immunosuppressive Therapy Including Rituximab for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Adult-Onset Still's Disease.Monocyte MicroRNA Expression in Active Systemic Juvenile Idiopathic Arthritis Implicates MicroRNA-125a-5p in Polarized Monocyte Phenotypes.Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies.Macrophage activation syndrome: early diagnosis is key
P2860
Q30235998-3AD7242B-08E0-4610-8328-4A9421DFF3D7Q36990716-D360B981-49A9-4BEB-A4C7-748BFFB5DD09Q37589316-A91F26D2-F9B5-4899-94E7-9D47D6625F67Q38575277-3AEADBED-003F-420B-A363-EAF1402B5BDAQ38633441-9CC8C448-C569-4F99-BA0D-1C101D91BCC8Q38637780-E9ABEB03-6484-4381-9791-7E756F297D38Q38786756-3796CC53-A253-4201-8AF9-8A71E1C4F7F6Q38793724-1410B25B-BA11-488D-84BF-6D9AF1357E83Q38883228-0A8E9DA5-53DC-479A-8078-7A6F08393019Q39144075-22FCAEAB-942C-4B0D-8C15-C40A7F74B1EEQ39424746-249E8973-77E6-44C2-924C-B2C0E840BD61Q40395354-DD10E6FB-9315-4C28-A02F-B5C60CCB26FFQ40959067-FB890036-8E7A-4C99-9CDE-1BCAA47858E1Q47111826-DC964B31-DD22-4CA4-8028-4619001397B4Q47150341-5624EE7C-CF43-462F-86E4-4EB170F0BC76Q47931407-56403761-B20C-45B0-8344-A3F5E34125DBQ50224636-8F755C9E-9EC1-4A33-BFC1-82F845FE447EQ58781634-D648F795-ABB8-43FF-AA48-D126542F18BD
P2860
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Rate and Clinical Presentation ...... itis Treated With Canakinumab.
@en
type
label
Rate and Clinical Presentation ...... itis Treated With Canakinumab.
@en
prefLabel
Rate and Clinical Presentation ...... itis Treated With Canakinumab.
@en
P2093
P2860
P356
P1476
Rate and Clinical Presentation ...... itis Treated With Canakinumab.
@en
P2093
Alberto Martini
Alexei A Grom
Daniel Lovell
Hermine I Brunner
Karine Lheritier
Karolynn Leon
Ken Abrams
Norman T Ilowite
Paediatric Rheumatology Intern ...... logy Collaborative Study Group
Virginia Pascual
P2860
P304
P356
10.1002/ART.39407
P577
2015-08-28T00:00:00Z